A wave of innovations across antibody-drug conjugates, synergistic combinations, and expanding biomarkers is transforming the genitourinary cancer landscape from metastatic rescue toward curative, earlier-line paradigms.
April 2026
Long-term CheckMate 9ER results show deeper tumor shrinkage with cabozantinib plus nivolumab and predicts longer survival and durable responses in advanced renal cell carcinoma.
Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.
CAPItello-281 shows capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.
Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.
Phase 2 results showed efficacy and tolerability of disitamab vedotin in pretreated HER2+ and HER2-low urothelial cancer.
In certain patients with prostate cancer, darolutamide enhanced PSMA expression, according to the Daro-PET study.
Neoadjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival compared with gemcitabine plus cisplatin.